The late-stage trial of Revlimid (lenalidomide) for the treatment of advanced prostate cancer has been discontinued after preliminary data shows that it does not extend survival! The independent monitoring committee recommended that the pivotal Phase III Mainsail trial be halted after it determined that adding Revlimid to standard treatments would not significantly increase the overall [...]
Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]
The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]
Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Notice this trial has the same criteria as [...]
According to a an article published in the January 2012 issue of Cancer Prevention Research, estrogen may play a role in Melanoma recurrences! The article described a large cohort study of women who were put on an anti-estrogen therapy. The study concluded that those women on the anti-estrogen therapy had a lower risk of melanoma. [...]